{Reference Type}: Journal Article
{Title}: Evaluation of Serum Sestrin 2 Levels in Patients Diagnosed with Endometrial Polyps and Uterine Leiomyomas.
{Author}: Bornaun T;Akkaya S;Güven HZ;
{Journal}: J Clin Med
{Volume}: 13
{Issue}: 12
{Year}: 2024 Jun 11
{Factor}: 4.964
{DOI}: 10.3390/jcm13123413
{Abstract}: Background/Objectives: This study investigates the correlation between the serum levels of Sestrin 2 and the presence of endometrial polyps or uterine leiomyomas, aiming to enhance the understanding of the pathophysiology underlying these gynecological conditions and evaluate the potential of Sestrin 2 as an early diagnostic biomarker. Methods: In a prospective case-control format, patients with preliminary diagnoses of endometrial polyps or uterine leiomyomas confirmed by histopathological analysis following surgery were included. This study analyzed serum Sestrin 2 levels across different patient groups, revealing significant variations that underscore the diagnostic value of Sestrin 2. Results: Elevated serum Sestrin 2 levels were observed in patients with endometrial polyps and uterine leiomyomas compared to the control group, suggesting its utility as a novel marker for early detection. Conclusions: The study indicates the promising role of serum Sestrin 2 levels as a valuable biomarker for early diagnosis of endometrial polyps and uterine leiomyomas, advocating for further research into its diagnostic and therapeutic potential.